Scientific R&D Underway for Therapeutic Antibodies Against COVID-19 by DBT/ Anti-COVID Consortium
There are lesser doubts to say that the biggest problem of our lifetime ahead of the entire world is the outbreak of COVID-19. Be it administration, social system, economy or daily lifestyle, every single aspect is affected. Economists are shouting for a crisis situation, the industry is crying for immediate action plan for their survival, the healthcare system is under tremendous pressure to outperform. But the most important area is pharmaceutical or healthcare research. This aspect is very critical and have the potential to bring our lives back on track of normalcy. And research and development are happening at a fast pace globally.
COVID-19 is caused by the novel SARS coronavirus-2 (SARS-CoV-2) and it is resulting in many deaths. However, a large number of infected people are also recovering despite not having any specific treatment. This is because of antibodies produced within the body in response to the virus invasion.
Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for the treatment of numerous disease conditions such as Diphtheria, Tetanus, Rabies, and Ebola. Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2.
In India, one such effort is being led by Professor Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology, Government of India.
Professor Chaudhary’s group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection.
These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes.
This work is being undertaken as part of an Anti-COVID consortium under the leadership of Prof. Chaudhary and involving Dr. Amulya Panda at National Institute of Immunology and Dr. Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).